Phase 1 open-label, multicenter, dose-escalation clinical study of the safety and tolerability of SNS-032, a novel cyclin-dependent kinase inhibitor, administered to patients with select advanced solid tumors

Trial Profile

Phase 1 open-label, multicenter, dose-escalation clinical study of the safety and tolerability of SNS-032, a novel cyclin-dependent kinase inhibitor, administered to patients with select advanced solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2012

At a glance

  • Drugs SNS 032 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Sponsors Sunesis Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2012 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
    • 06 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jul 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top